
BioHarvest Sciences Inc. (NASDAQ:BHST – Free Report) – HC Wainwright lowered their FY2026 earnings per share estimates for shares of BioHarvest Sciences in a research report issued on Monday, November 16th. HC Wainwright analyst A. Dayal now forecasts that the company will earn ($0.62) per share for the year, down from their prior estimate of ($0.59). The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q4 2026 earnings at ($0.19) EPS, FY2027 earnings at ($0.25) EPS, FY2028 earnings at $0.11 EPS, FY2029 earnings at $0.56 EPS and FY2030 earnings at $1.12 EPS.
Other analysts have also recently issued reports about the company. Roth Capital cut their price objective on BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Monday, September 14th. Finally, Maxim Group dropped their price objective on shares of BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $6.50.
Read Our Latest Stock Analysis on BHST
BioHarvest Sciences Stock Down 11.6%
BHST stock opened at $1.22 on Wednesday. The company has a market cap of $23.94 million, a price-to-earnings ratio of -2.30 and a beta of 0.93. BioHarvest Sciences has a twelve month low of $0.91 and a twelve month high of $7.20. The business has a 50 day moving average price of $1.62 and a two-hundred day moving average price of $3.04.
BioHarvest Sciences (NASDAQ:BHST – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The company had revenue of $7.87 million during the quarter, compared to analyst estimates of $9.31 million. BioHarvest Sciences had a negative return on equity of 55.88% and a negative net margin of 34.67%.
Institutional Trading of BioHarvest Sciences
A hedge fund recently raised its position in BioHarvest Sciences stock. TD Waterhouse Canada Inc. raised its holdings in BioHarvest Sciences Inc. (NASDAQ:BHST – Free Report) by 83.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 43,827 shares of the company’s stock after buying an additional 20,000 shares during the quarter. TD Waterhouse Canada Inc. owned about 0.22% of BioHarvest Sciences worth $64,000 at the end of the most recent quarter.
About BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company that develops plant-based ingredients and consumer products using its proprietary Botanical Synthesis platform. The technology grows selected plant cells in controlled bioreactors, offering an alternative to cultivating and processing whole plants. The company’s best-known product is VINIA, a dietary supplement made from red grape cells. BioHarvest also works to develop additional botanical ingredients and products for consumer markets, including nutraceuticals and cosmetics.
Featured Articles
- Five stocks we like better than BioHarvest Sciences
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for BioHarvest Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioHarvest Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
